成人急性白血病患者耐药铜绿假单胞菌血流感染的危险因素与结局
该单中心回顾性研究纳入2014年1月至2019年12月住院的293例急性白血病合并铜绿假单胞菌血流感染患者。结果显示,MDR-PA血流感染患者30天死亡率为28.9%,显著高于非MDR-PA患者的5.5%(P < .001);既往使用喹诺酮类和哌拉西林/他唑巴坦与MDR-PA血流感染独立相关,而MDR-PA血流感染、肛周感染、肺部感染和年龄≥55岁是30天死亡的独立危险因素。
要点
- MDR-PA血流感染患者30天死亡率显著高于非MDR-PA患者(28.9% vs 5.5%,P < .001)。
- 既往使用喹诺酮类或哌拉西林/他唑巴坦与MDR-PA血流感染独立相关。
- MDR-PA血流感染、肛周感染、肺部感染和年龄≥55岁是30天死亡的独立危险因素。
核心结论
- MDR增加PA血流感染患者的死亡风险,既往抗生素暴露是MDR-PA血流感染的重要相关因素。
- 基于当地药敏和临床特征的合理抗生素使用有助于减少耐药和死亡。
研究设计与样本
- 单中心回顾性研究,纳入2014年1月至2019年12月住院的急性白血病合并PA血流感染患者293例。
- 采用Kaplan-Meier法绘制生存曲线,并进行多因素logistic回归分析。
主要发现
- 293例PA血流感染患者中,55例(18.8%)在血流感染发生后48小时内接受了不恰当的经验性抗生素治疗。
- MDR-PA血流感染患者中高达65.8%接受了不恰当的经验性治疗。
- 所有患者30天死亡率为8.5%,MDR-PA血流感染和非MDR-PA血流感染患者分别为28.9%和5.5%(P < .001)。
- 多因素分析显示,既往使用喹诺酮类(OR 5.851,95%CI 2.638-12.975)和哌拉西林/他唑巴坦(OR 2.837,95%CI 1.151-6.994)与MDR-PA血流感染独立相关。
- MDR-PA血流感染(OR 7.196,95%CI 2.773-18.668)、肛周感染(OR 4.079,95%CI 1.401-11.879)、肺部感染(OR 3.028,95%CI 1.231-7.446)和年龄≥55岁(OR 2.871,95%CI 1.057-7.799)是30天死亡的独立危险因素。
临床怎么用
- 对急性白血病合并PA血流感染患者,应评估既往喹诺酮类和哌拉西林/他唑巴坦暴露史以警惕MDR-PA。
- 经验性抗生素选择应参考当地药敏数据,并关注肛周感染、肺部感染及年龄≥55岁等高死亡风险因素。
局限性
- 单中心回顾性研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pseudomonas aeruginosa (PA) bloodstream infection (BSI) is a common complication in patients with acute leukemia (AL), and the prevalence of antibiotic-resistant strains poses a serious problem. However, there is limited information regarding antibiotic resistance, clinical characteristics, and outcomes of PA BSI in AL patients. This study explored characteristics associated with the clinical outcomes of AL patients with PA BSI and analyzed factors associated with BSI caused by multidrug-resistant (MDR) or carbapenem-resistant strains. METHODS: This single-center retrospective study enrolled hospitalized AL patients who developed PA BSI during January 2014-December 2019. The Kaplan-Meier method was used to plot survival curves. Multivariate logistic regression analyses were also performed. RESULTS: Of 293 eligible patients with PA BSI, 55 (18.8%) received inappropriate empirical antibiotic therapy within 48 hours of BSI onset, whereas up to 65.8% MDR-PA BSI patients received inappropriate empirical treatment. The 30-day mortality rate was 8.5% for all patients. However, the 30-day mortality rates were 28.9% and 5.5% in MDR-PA BSI and non-MDR-PA BSI patients, respectively (P < .001). On multivariate analysis, previous use of quinolones (odds ratio [OR], 5.851 [95% confidence interval {CI}, 2.638-12.975]) and piperacillin/tazobactam (OR, 2.837 [95% CI, 1.151-6.994]) were independently associated with MDR-PA BSI; and MDR-PA BSI (OR, 7.196 [95% CI, 2.773-18.668]), perianal infection (OR, 4.079 [95% CI, 1.401-11.879]), pulmonary infection (OR, 3.028 [95% CI, 1.231-7.446]), and age ≥55 years (OR, 2.871 [95% CI, 1.057-7.799]) were independent risk factors for 30-day mortality. CONCLUSIONS: MDR increases mortality risk in PA BSI patients, and previous antibiotic exposure is important in MDR-PA BSI development. Rational antibiotic use based on local antimicrobial susceptibility and clinical characteristics can help reduce antibiotic resistance and mortality.
引用
- Zhao Y, Lin Q, Liu L, et al. Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia. Clin Infect Dis. 2020. PMID: 33367574. doi:10.1093/cid/ciaa1522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。